Interim Results From The First Large Human Trials Testing Whether GLP-1 Drugs (Such As Semaglutide) Slow Aging Are Expected By 2031, Clarifying Whether These Drugs, Which Extended Mouse Lifespan By About 12 Percent, Affect Biological Aging Markers In Humans.

Can GLP-1 Medications Really Slow Down Aging?

In recent years, GLP-1 agonists (such as semaglutide), which have revolutionized the treatment of obesity and diabetes, have now also become a focus of research into longevity. But can these medications actually slow down the aging process in humans? The results of the first major human trials may not be clear until 2031.

12% Longer Lifespan in Mice: Scientific Evidence

A study published in Nature found that elderly male mice treated with semaglutide lived an average of 834 days, while control group mice lived for 742 days. This represents a 12% increase in lifespan. Researchers believe this effect is linked to the drugs reducing inflammation and lowering metabolic stress. Given that accelerated biological aging is driven by heightened chronic immune activation, it’s suggested that GLP-1 medications could suppress this process and slow down aging.

Human Trials: Eli Lilly and the TAME Protocol

There is currently no scientific evidence to suggest that GLP-1 should be used in healthy people for longevity. However, Eli Lilly has announced plans for a human trial using the TAME (Targeting Aging with Metformin) protocol - an FDA-approved trial utilizing an aging composite endpoint. This could be the first major corporate step where the drug giant officially targets aging as an indication. Results from the trial are expected to be released around 2031.

When Will Biological Age Markers Become Clear?

The results of these trials will show whether drugs like semaglutide affect human biological age markers (such as the epigenetic clock, levels of inflammation). If the results are positive, GLP-1 medications could become the first proven pharmacological tool in anti-aging medicine. However, experts emphasize that more data is needed before these drugs can be used not just for weight loss, but as a treatment targeting the aging process itself.

Frequently Asked Questions

Did GLP-1 Medications Really Extend The Lifespan Of Mice By 12%?

Yes, in the Nature published study, mice treated with semaglutide lived an average of 834 days, while the control group lived for 742 days. This indicates a 12% lifespan increase. However, these results cannot yet be directly applied to humans.

When Will The Human Trial Using GLP-1 Be Completed?

The interim results of Eli Lilly’s planned trial using the TAME protocol are expected to be released by 2031. This trial will measure the drugs' effect on biological age markers.

Can I Use GLP-1 Medications Now For Longevity?

No, there is currently no scientific evidence that they slow down aging in healthy people. These medications are only approved for the treatment of obesity or diabetes and are not recommended for use with the intention of promoting longevity. Results from the trial must be awaited.